CME Group — FY2026Q2 Earnings Review
BUY
NASDAQ: CME | First miss in at least 12 quarters: revenue and adjusted EPS both missed as ADV growth stalled to roughly flat against a record Q2'25 comp — a base-effect deceleration, not a demand break, with market data hitting a record +20.2% YoY and July ADV already tracking +18%.
Revenue Miss
-1.9%
$1,706.2M actual vs $1.74B consensus; YoY growth +14.5% (Q1) -> +0.8% (Q2)
EPS Miss (adj.)
-0.7%
$2.99 actual vs $3.01 consensus; first miss in 12+ quarters
Growth Trajectory
Decelerating
Rev YoY -1,364bps, EPS YoY -1,899bps QoQ -- sharpest swing in the 8Q window
Guidance vs Consensus
Reaffirmed
FY26 opex $1.695B / capex ~$85M / tax 23.5-24.5% held flat, 3rd straight quarter
Executive summary — what's new this quarter
CME Group reported FY2026Q2 on July 22, 2026 (before market open) and broke a 12-quarter unbroken beat streak on both lines. Revenue of $1,706.2M missed the ~$1.74B Street consensus by -1.9%, and adjusted diluted EPS of $2.99 missed the $3.01 consensus by -0.7% (GAAP diluted EPS of $2.88 missed by a wider -4.3%). The cause was a stalled Average Daily Volume (ADV) print — 29.8M contracts, essentially flat (-1.3% YoY) against Q2'25's own record 30.2M — after Q1'26 posted a blow-out +21.7% YoY comp that appears to have been extrapolated into the consensus model. Operating and EBITDA margins both compressed ~185bps YoY, the sharpest margin decline in the trailing two-year window.
New guidance: none, in substance. CME's only three guided items — FY2026 adjusted opex ex-license fees ($1.695B), capex (~$85M), and adjusted effective tax rate (23.5%–24.5%) — were reaffirmed unchanged for a third straight quarter, and notably were not even raised on the call this time (no analyst asked; reaffirmation is inferred from the unchanged Daloopa series, not a verbal restatement). The one hard forward data point management did offer: "third quarter volumes have started out strong, with July to date tracking 18% ahead of last year" (CFO/incoming CEO Lynne Fitzpatrick) — framing the Q2 shortfall as a comp-timing issue rather than a demand problem.
Tone shift: management moved from Q1's confident, record-setting, initiative-forward posture to a materially more defensive Q2 call — roughly 7 of 12 analyst questions centered on perpetual-futures/prediction-market disintermediation risk, and Terry Duffy spent the bulk of the call defending CME's institutional-hedging moat rather than discussing growth initiatives. Two new, specific risk disclosures appeared this quarter that were absent in Q1: the CFTC's stay of CME's self-certified 24/7 crude oil contract, and active CME-vs-CFTC litigation over the swaps-vs-futures classification of perpetual futures (government response due ~late August 2026).
Contradictions: two internally-inconsistent statement pairs were identified — (1) Terry Duffy's Q1 claim that perpetuals are "against the law" in the U.S. is undercut by Q2 management commentary describing a live, CFTC-regulated Kalshi Bitcoin perpetual trading since May/June, and by CME's own litigation framing the legal classification as unsettled ("swaps, not futures"); (2) two incompatible daily margin-savings totals were cited on the same Q2 call ($95B headline vs. $27B from a rates executive, both using all-encompassing "futures/options/swaps/cash" language) — a pattern that repeats verbatim from the Q4 FY2025 call ($80B vs. $25B). See the Contradictions section below for full detail.
Upcoming catalysts: Single Stock Futures launched July 27, 2026 (5 days after this print); Compute Futures with Silicon Data targeted for H2 2026; Treasury Link guided to Q4 2026 ahead of the SEC's Treasury/repo central-clearing mandate; and the CFTC litigation response due ~late August 2026 is the key regulatory overhang to watch next quarter.
Key metrics & trends (12 quarters)
CME is an exchange operator: Average Daily Volume (ADV) × Average Rate Per Contract (RPC) drives Clearing & transaction fees; Market data & information services is the faster-growing, subscription-like second revenue line. CME has no cost-of-goods-sold line, so operating margin is used in place of gross margin. GAAP and Adjusted diluted EPS are distinct Daloopa series (a prior-run fact file had conflated them for some quarters) — both are shown below.
| Metric | 23Q3 | 23Q4 | 24Q1 | 24Q2 | 24Q3 | 24Q4 | 25Q1 | 25Q2 | 25Q3 | 25Q4 | 26Q1 | 26Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADV (M contracts/day) | 22.3 | 25.5 | 26.4 | 25.9 | 28.3 | 25.5 | 29.8 | 30.2 | 25.3 | 27.4 | 36.2 | 29.8 |
| ADV YoY | n/a | n/a | n/a | n/a | +26.9% | +0.0% | +12.9% | +16.6% | -10.6% | +7.5% | +21.5% | -1.3% |
| Avg rate/contract, RPC ($) | 0.707 | 0.682 | 0.695 | 0.708 | 0.666 | 0.701 | 0.686 | 0.690 | 0.702 | 0.707 | 0.652 | 0.678 |
| Clearing & transaction fees ($M) | 1,085.5 | 1,184.5 | 1,208.9 | 1,249.9 | 1,297.1 | 1,232.3 | 1,337.3 | 1,388.0 | 1,227.9 | 1,327.9 | 1,542.6 | 1,352.5 |
| Clearing fees YoY | n/a | n/a | n/a | n/a | +19.5% | +4.0% | +10.6% | +11.0% | -5.3% | +7.8% | +15.4% | -2.6% |
| Market data & info svcs ($M) | 167.6 | 167.2 | 175.4 | 175.0 | 178.2 | 181.6 | 194.5 | 198.1 | 202.5 | 208.0 | 224.1 | 238.1 |
| Market data YoY | n/a | n/a | n/a | n/a | +6.3% | +8.6% | +10.9% | +13.2% | +13.6% | +14.5% | +15.2% | +20.2% (record) |
| Total revenue ($M) | 1,337.8 | 1,439.3 | 1,487.9 | 1,532.5 | 1,584.4 | 1,525.3 | 1,642.3 | 1,692.0 | 1,537.6 | 1,648.7 | 1,880.1 | 1,706.2 |
| Total revenue YoY | n/a | n/a | n/a | n/a | +18.4% | +6.0% | +10.4% | +10.4% | -3.0% | +8.1% | +14.5% | +0.8% |
| Operating margin (GAAP) | 61.3% | 60.0% | 64.5% | 65.3% | 64.6% | 62.1% | 67.5% | 66.7% | 63.3% | 61.8% | 69.7% | 64.9% |
| Operating margin YoY (bps) | n/a | n/a | n/a | n/a | +333 | +212 | +297 | +145 | -139 | -25 | +219 | -186 |
| Adjusted diluted EPS ($) | 2.25 | 2.37 | 2.50 | 2.56 | 2.68 | 2.52 | 2.80 | 2.96 | 2.68 | 2.77 | 3.36 | 2.99 |
| Adjusted diluted EPS YoY | n/a | n/a | n/a | n/a | +19.1% | +6.3% | +12.0% | +15.6% | +0.0% | +9.9% | +20.0% | +1.0% |
| GAAP diluted EPS ($) | 2.06 | 2.23 | 2.35 | 2.42 | 2.50 | 2.40 | 2.62 | 2.81 | 2.49 | 3.24 | 3.18 | 2.88 |
| GAAP diluted EPS YoY | n/a | n/a | n/a | n/a | +21.4% | +7.6% | +11.5% | +16.1% | -0.4% | +35.0% | +21.4% | +2.5% |
Read-through: decelerating on every axis this quarter. Revenue growth stepped down from +14.5% (Q1'26) to +0.8% (Q2'26); ADV flipped from +21.5% to -1.3% YoY (first decline in the 8-quarter window); operating margin fell 186bps YoY, the worst compression in the window; and adjusted EPS growth compressed from +20.0% to +1.0%, missing consensus. The lone structurally positive signal is market data's acceleration to a record +20.2% YoY, decoupling from the cyclical clearing & transaction-fee line, which posted its first YoY decline (-2.6%) in the window. Net read: this deceleration is volume/volatility-driven (macro, lapping CME's own record comp), not company-specific.
Data sourced from Daloopa (company_id 333). GAAP diluted EPS (series 4286773) and adjusted diluted EPS (series 4978909, CME's own non-GAAP reconciliation) are distinct series — this table separates them explicitly; all consensus comparisons elsewhere in this review use the adjusted basis, matching how Street consensus is built.
Beat / miss
CME's 12-quarter unbroken beat streak breaks in FY2026Q2. Adjusted diluted EPS of $2.99 missed the $3.01 Street consensus by -0.7%, and revenue of $1,706.2M missed the ~$1.74B consensus by -1.9%. This is CME's first miss (on any basis) in at least 12 quarters, capping a multi-quarter trend of steadily compressing beat magnitude — the Street has finally modeled CME's ADV closely enough to catch it out. Cause: Q2 ADV of 29.8M contracts grew only ~1% YoY (vs. FY2025Q2's 30.2M record), well below the double-digit growth baked into consensus after Q1'26's 21.7%-YoY blow-out comp, as a tough April comparison offset stronger May/June.
| Metric | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 (this qtr) |
|---|---|---|---|---|---|---|---|---|
| EPS surprise (adj.) | +1.1% | +3.3% | +4.5% | +1.0% | +1.9% | +0.7% | +1.5% | -0.7% |
| Revenue surprise | n/a | n/a | +3.3% | +0.7% | n/a | n/a | +1.6% | -1.9% |
Green = beat (darker = larger); red = miss; grey = consensus not reliably archived. Q2'26 is CME's first EPS/revenue miss on record in this window.
| Window | EPS beat rate | Avg. surprise | Read |
|---|---|---|---|
| L12Q (Q3'23-Q2'26) | 11/12 (91.7%) | ~+1.9% | Still a beater on trailing-year basis, but streak just broke |
| L4Q (Q3'25-Q2'26) | 3/4 (75%) | ~+0.9% | Miss this quarter drags the near-term rate down materially |
| Q3'23-Q2'24 (oldest 4) | 4/4 | ~+2.4% | Big beats, volume surprises |
| Q3'24-Q2'25 (middle 4) | 4/4 | ~+2.7% | Still solid, rate-per-contract/margin driven |
| Q3'25-Q2'26 (last 4) | 3/4 | ~+0.9% | Beats shrink to near-zero, culminating in a miss |
Pattern: consistent beater whose streak just broke — mixed-to-deteriorating, not yet "misser." CME ran 12/12 quarterly EPS beats through Q1'26; FY2026Q2 is the first miss in this window on both revenue and EPS. This is consistent with a highly modelable, ADV-transparent business where the Street's model simply caught up — one quarter of decelerating volume growth (a hard April comp) was enough to flip a small structural beat into a small miss. It is not evidence of fundamental deterioration (H1 2026 was still CME's strongest half in company history), but the "automatic beat" thesis needs revisiting — the next 2-3 quarters (against progressively tougher YoY comps) are the read on whether this was a one-off comp issue or a genuine pattern shift.
Actuals — Daloopa (company_id 333; Total revenues series 1195088; Adjusted Diluted EPS series 1195255; GAAP Diluted EPS series 1195253). Consensus/surprise — Zacks/aggregated Street at report date (Bloomberg & Visible Alpha MCPs offline this run, flagged). Management commentary — CME FY2026Q2 earnings call transcript, 2026-07-22.
Guidance deep dive
CME issues no quarterly or annual revenue/EPS guidance — its clearing & transaction-fee revenue is volume/rate-driven and management does not forecast volume. The only formal, numeric guidance CME gives each quarter is a full-year adjusted operating expense (ex-license fees) figure, a full-year capex figure, and a full-year adjusted effective tax-rate range.
Waterfall — the one metric CME actually guides: FY2026 adjusted opex ex-license fees
| Stage | Value | Delta vs. prior stage |
|---|---|---|
| Initial framework (set FY2025Q3 call) | $1.625B | — |
| Formal FY26 guide (set FY2025Q4 call) | $1.695B | +$70M (raised) |
| Reaffirmed (FY2026Q1 call, Apr 22, 2026) | $1.695B | $0 (held) |
| Reaffirmed (FY2026Q2 call, Jul 22, 2026) — this quarter | $1.695B | $0 (held) |
Read: guidance moved once (raised $70M when formalized at Q4'25), then has been flat for three straight quarters. Notably, the FY2026Q2 transcript contains no mention of "guidance" or the $1.695B figure at all — unlike Q1, no analyst raised the topic this quarter, and management did not proactively reaffirm it in prepared remarks. The reaffirmation is inferred from the unchanged Daloopa-tagged guidance series, a mild disclosure/tone data point.
FY2026 guided items — new vs. prior
| Metric (FY2026) | Prior guide (Q1'26 call) | New guide (Q2'26 call) | vs. prior |
|---|---|---|---|
| Adj. opex ex-license fees | $1.695B | $1.695B | Unchanged |
| Capital expenditure | ~$85M | ~$85M | Unchanged |
| Adj. effective tax rate | 23.5%-24.5% | 23.5%-24.5% | Unchanged |
| Revenue / EPS / margin | Not guided | Not guided | N/A |
Guidance discipline check: adjusted expense ex-license ran ~$405M in Q1'26 and ~$412M in Q2'26 — an H1 total of ~$817M against the $1.695B full-year guide, implying an H2 budget of ~$878M (a ~7% step-up half-over-half), consistent with management's comment that occupancy and technology costs (Dallas facility, cloud migration) would continue to grow through the year. Guidance is being held even as implied spend accelerates into H2.
Reported trend vs. what guidance implies (revenue/EPS not guided — shown for context)
| Period | Revenue YoY | Adj. EPS YoY | Adj. op. margin YoY |
|---|---|---|---|
| FY2026Q1 (reported) | +14.5% | +20.0% | roughly flat |
| FY2026Q2 (just reported) | +0.8% | +1.0% | -200bps |
| FQ+1 (Q3 2026, consensus-implied) | ~+11.7% (weak comp) | ~+11.9% | Not guided |
The apparent Q3 2026 consensus "acceleration" (+11.7%/+11.9%, web-sourced, last resort — not Bloomberg/VA-verified) is largely a weak-comp effect: FY2025Q3 revenue was itself a sequential decline from FY2025Q2 (CME's typical summer-lull seasonality). It reflects an easy prior-year base more than a change in trajectory — consistent with, but not proof of, management's "July tracking +18%" comment.
Management tone: Q1 2026 vs. Q2 2026
| Dimension | Q1'26 call | Q2'26 call |
|---|---|---|
| Opening framing | "Record-breaking start" — record ADV across all 6 asset classes simultaneously; explicit confidence. | Q2 ADV "within 1% of our record" — a near-miss framed positively; H1 framed as "strongest in company history" in aggregate. |
| Guidance emphasis | Analyst directly probed expense-guidance pacing; CFO walked through drivers, reaffirmed comfort. | No analyst asked about guidance at all; management did not proactively restate the figure. |
| Dominant Q&A topic | Broad-based: cross-margining, tokenization, settlement changes, capital allocation — confident, growth-forward. | Perpetual-futures competitive threat dominated — ~7 of 12 questions; management on the defensive. |
| New risk disclosures | None beyond standard safe-harbor language. | CFTC stay of 24/7 crude self-certification; active CME-vs-CFTC litigation (response due ~late Aug 2026). |
Net read: guidance itself was held flat for a third straight quarter with minimal on-call emphasis. The more consequential shift is qualitative — management's tone moved from Q1's confident, initiative-forward posture to Q2's defensive posture, alongside new and specific regulatory/litigation risk disclosures that did not exist as of the Q1 call.
Guidance series confirmed via Daloopa's "Guidance" hierarchy (adjusted operating expense, capex, tax rate — series IDs 6455947, 2509724, 1194992/1194993). Transcript quotes from CME_FY2026Q1.txt and CME_FY2026Q2.txt (this workspace). Q3 2026 / FY2027 consensus figures are web-sourced, last resort (Bloomberg MCP and Visible Alpha both unreachable this run).
Historical performance — 8-quarter trajectory
| Metric | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % | +18.43% | +5.98% | +10.38% | +10.41% | -2.95% | +8.09% | +14.48% | +0.84% |
| Rev accel (bps QoQ) | +577 | -1,246 | +440 | +3 | -1,336 | +1,104 | +639 | -1,364 |
| EPS YoY % | +19.11% | +6.33% | +12.00% | +15.63% | 0.00% | +9.92% | +20.00% | +1.01% |
| EPS accel (bps QoQ) | +781 | -1,278 | +567 | +363 | -1,563 | +992 | +1,008 | -1,899 |
Accel = current-quarter YoY% minus prior-quarter YoY%, in basis points. Positive = accelerating growth; negative = decelerating growth.
Trough — Q3'25
Revenue YoY turned slightly negative (-2.95%), EPS YoY flatlined (0.00%) — the low point of the series, as 2024's elevated volatility comps rolled off and volumes normalized (ADV 25.3M, the low of the window).
Sharp reacceleration — Q4'25 to Q1'26
Two consecutive positive-acceleration quarters (Rev +1,104bps then +639bps; EPS +992bps then +1,008bps), culminating in Q1'26's record ADV of 36.2M contracts (+21.7% YoY) on tariff/rate volatility — the strongest quarter in the series (Rev +14.48%, EPS +20.00%).
Sharpest deceleration — Q2'26 (this quarter)
The single largest swing in the series (Rev -1,364bps, EPS -1,899bps) as growth collapsed to roughly flat (Rev +0.84%, EPS +1.01%). This is a base-effect story, not demand deterioration: Q2'26 ADV (29.8M) was within 1% of Q2'25's own record print, so the deceleration reflects lapping a tough comp rather than a volume decline.
Plain-English assessment: CME's growth is lumpy and volatility-driven, not a smooth compounder — over this 8-quarter window, revenue YoY swung from -2.95% to +18.43% and EPS YoY from 0.00% to +20.00%, with four separate acceleration/deceleration reversals. The pattern tracks the macro-volatility cycle directly. Zooming out past the quarter-to-quarter noise, H1 2026 in aggregate was still management's strongest half in company history (volume +10% YoY, revenue +8% YoY, adjusted EPS +10% YoY), and market data revenue — a steadier, subscription-like layer — posted its 33rd consecutive quarter of YoY growth and 8th consecutive record quarter, cushioning the transaction-fee cyclicality above. Management flagged July-to-date ADV tracking +18% YoY, pointing to Q3'26 reaccelerating again rather than the Q2'26 dip persisting.
Data sourced from Daloopa (company_id 333); management commentary sourced from the CME FY2026Q2 earnings call transcript, 2026-07-22.
Key catalysts
The dominant near-term catalyst cluster is regulatory (perpetuals litigation timeline, CFTC's mixed self-certification treatment, pending prediction-market rule) layered on top of a genuine product-launch calendar that management is explicitly using to counter the "perpetuals-as-existential-threat" narrative the stock sold off on.
| Catalyst | Timing | Management commentary | Street / consensus view |
|---|---|---|---|
| CFTC litigation — perpetual futures (Kalshi/Coinbase) | Filed Jun 18, 2026; CFTC response due ~late Aug/Sept 2026 | Duffy: perpetuals are legally swaps, not futures; CME has specs ready but sees no institutional demand (94% of volume institutional) | KBW upgraded to Outperform ($305 PT) calling risk overblown; 2 Strong Sell / 1 Moderate Sell of 18 remain cautious |
| Single Stock Futures launch | Live Jul 27, 2026 (5 days after this print) | Winkler: "the single biggest retail growth catalyst of the year," 35+ retail partners targeting day-one readiness | Confirmed via CME PR (Jun 30); qualitative growth-optionality, not yet in published models |
| Compute Futures (with Silicon Data) | Partnership announced May 12; product H2 2026, pending regulatory review | Duffy: "excited by the growth of this product"; benchmark on spot hourly NVIDIA H100 GPU rental cost | Press frames it "world's first" compute/GPU futures market — novel category, no established consensus estimate |
| Treasury Link | Guided to Q4 2026, pending regulatory review | Dennis: connects two largest U.S. Treasury liquidity pools ahead of the central-clearing mandate | SEC mandate requires centrally-cleared cash Treasury from Dec 31, 2026 and repo from Jun 30, 2027 — a hard regulatory tailwind |
| Prediction/event markets | CFTC proposed rule Jun 10, ~45-day comment period | Fitzpatrick: ~525M event contracts since launch, 140K accounts (+13% QoQ); data monetization still "a bit of a ways off" | Kalshi/Polymarket expanding beyond sports into politics/climate/FX — widening competitive front |
| 24/7 trading rollout — mixed outcome | Crypto/gold live; crude oil stayed by CFTC Jul 9, one day before launch | Duffy calls CFTC's inconsistent treatment "a little concerning" | CFTC Chair Selig called self-certification timing "wholly inappropriate" — incremental approval risk for future launches |
| Project Vault / critical-minerals onshoring | Ongoing macro/policy tailwind | Sammann: copper volumes +4% YTD, record ~700K short tons in COMEX warehouses, record steel open interest | No specific consensus estimate; treated as structural tailwind to the metals complex |
| CEO succession (Duffy to Fitzpatrick) | Effective Mar 1, 2027 | Fitzpatrick: "not a strong departure from what we've delivered... I wouldn't expect a large-scale departure" | Consistent with prior disclosure; no incremental Street commentary this run |
Sentiment-inversion read: consensus reaction to the perpetuals headline risk has been sharply negative (June selloff), while KBW's contrarian upgrade and management's repeated, specific pushback (94% institutional volume, cost-of-carry math, Kalshi sized at ~1/20th-1/40th CME's daily notional) suggest the market may be over-pricing the threat relative to what CME's own customer conversations indicate — worth tracking as the CFTC litigation timeline plays out.
Sources: CME FY2026Q2 earnings call transcript (2026-07-22); web/press coverage — CryptoDaily, Yahoo Finance, PRNewswire, Investing.com, CME investor relations, A-Team Insight, J.P. Morgan, CFTC.gov, CryptoBriefing, VaaSBlock, Axios (full citation list in the run workspace). No S&P/Kensho, Visible Alpha, Bloomberg MCP, or Carbon Arc alt-data connectivity was available this run — alt-data marked not available throughout rather than fabricated.
Street Q&A
14 analyst questions from 11 sell-side analysts on the FY2026Q2 call. Scorecard: 10 Well Answered / 4 Deflected or Avoided. The four deflections cluster on regulatory/strategy/emerging-tech questions — not product or volume metrics, where management had numbers ready for everything.
| Analyst / topic | Management response (summary) | Badge |
|---|---|---|
| Fannon (Jefferies) — perpetuals customer demand | Duffy cited direct conversations with the #2 global energy commercial participant, who said "19 times" it does not want a perpetual product. | Well Answered |
| Kramm (UBS) — why no retail perpetuals | Funding-rate/auto-liquidation framework, then McCourt gave hard numbers: CME crypto $4.5-6.5B/day notional vs. Kalshi ~$270M/day. | Well Answered |
| Allen (KBW) — Compute Futures demand | Sammann laid out mechanics, partnership with Silicon Data, and user base (AI labs, cloud providers, banks). | Well Answered |
| Worthington (JPM) — Project Vault read-through to COMEX | Sammann gave quantified data: copper +4% YTD, record ~700K short tons in COMEX warehouses, record steel OI. | Well Answered |
| Moley (Piper Sandler) — CFTC oil-vs-gold inconsistency | Duffy pivoted to a grievance narrative (hot-dog-contest comparison) instead of addressing the regulatory read-through asked for. | Deflected |
| Bedell (Deutsche Bank) — equity perps process/structure/systemic risk | Four-part question, all parts addressed: legal position, clearing structure, license exclusivity, systemic-risk acknowledgment. | Well Answered |
| Blostein (Goldman) — Single Stock futures timing/distribution | Duffy on timing logic; McCourt on equity-complex ADV growth; Winkler quantified 35+ retail brokers ready day-one. | Well Answered |
| Budish (Barclays) — market data strength/sustainability | Winkler itemized drivers; Fitzpatrick proactively disclosed the ~$7M one-time audit/catch-up item unprompted. | Well Answered |
| Cyprys (Morgan Stanley) — prediction-market data monetization | Traction half answered with real numbers; monetization half explicitly punted ("a bit of a ways off"). | Deflected |
| Katz (TD Cowen) — Fitzpatrick's strategic priorities as incoming CEO | Almost entirely generic continuity language ("not a strong departure"), no concrete top-two-or-three list despite being asked for one. | Deflected |
| Katz (TD Cowen) — CFTC litigation timeline | Duffy gave a specific process: 60 days to respond (due August), judge assigned, next checkpoint named. | Well Answered |
| Clinch (Rothschild & Redburn) — perpetuals as symbiotic, not just a threat | Duffy: perpetual venues could act as an unpaid retail "incubator," named specific partners (NinjaTrader, Topstep). | Well Answered |
| Qi (RBC) — Gen AI as market-data demand driver | Winkler's response was almost entirely hedge language ("relatively early days"), no concrete product/revenue detail. | Deflected |
| Cyprys (follow-up) — vertically integrated D2C marketplaces | Duffy distinguished CME's neutral-facilitator model from vertically integrated venues; disclosed CME's own FCM was built for an FTX-style scenario. | Well Answered |
Deflection summary: (1) Moley's CFTC oil-vs-gold read-through was redirected to an unrelated grievance; (2) Cyprys' prediction-market data-monetization question got strong volume stats but no revenue-opportunity framework; (3) Katz's ask for Fitzpatrick's concrete top-2-3 CEO priorities produced only continuity boilerplate; (4) Qi's Gen-AI-as-data-driver question was answered with hedge language despite market data being the quarter's key growth story. Common thread: deflections cluster on forward-looking, less-quantifiable topics (regulatory strategy, new-CEO vision, emerging-tech demand) — not product or volume metrics.
Source: CME Group FY2026Q2 earnings call transcript, 2026-07-22 (this workspace's transcripts/ folder).
Contradictions
Scope reviewed: all 4 transcripts on disk (FY2025Q3 through FY2026Q2) plus this run's internal notes. Two internally-inconsistent statement pairs were found — ranked most material first.
CONTRADICTION 1 — "Perpetuals are against the law in the United States" (Q1) vs. management's own Q2 commentary on a live, trading U.S. perpetual product and CME's litigation treating the question as unsettled
| Source | Quote |
|---|---|
| Q1 FY2026 call (Terry Duffy, on S&P Dow Jones perpetual JV) | "First of all, perpetuals are against the law in the United States of America. That's first and foremost... They are not allowed under the Commodity Exchange Act of 2000." |
| Q2 FY2026 call (Tim McCourt, on retail perpetuals demand) | "...about $270 million at the Bitcoin perp introduced by Kalshi in the month of July... $10 million of open interest in the perpetual product that was introduced at the end of May, beginning of June." |
| Q2 FY2026 call (Terry Duffy, on equity perps) | "We still believe, and our litigation will show that these are swaps, not futures... We feel very confident that that is a swap contract to start." |
In April, Duffy told investors as flat fact that perpetuals "are against the law" and "not allowed" in the U.S. Three months later, CME's own head of equity/FX products cites a real, CFTC-regulated U.S. venue (Kalshi, a designated contract market) actively trading a Bitcoin perpetual with measurable daily notional and open interest since late May/early June 2026 — meaning a U.S. perpetual product had been operating for roughly two months before this call. Duffy's own framing shifted from "against the law" to "our litigation will show these are swaps, not futures" — conceding the legal classification is a contested, unresolved question being fought in front of a judge, not the settled illegality he asserted in Q1. The shift is never acknowledged on the Q2 call.
CONTRADICTION 2 — Two different "total" daily margin-savings figures cited on the same call, never reconciled, and the same pattern repeats a call earlier
| Source | Quote |
|---|---|
| Q2 FY2026 call (prepared remarks & Q&A, Terry Duffy) | "...saving our customers an average of over $95 billion in margin per day"; repeated in Q&A as "the $95 billion of efficiencies that that 130 million open interest receives on a daily basis." |
| Q2 FY2026 call (closing remarks, Mike Dennis) | "...alongside the $27 billion a day in margin savings across futures options, swaps, and cash." |
| Corroborating precedent — Q4 FY2025 call | Duffy: "$80 billion" across all six asset classes vs. Fitzpatrick (same call, Q&A): "$25 billion a day... inclusive of all of our futures and options, the swaps... as well as the offsets with FICC." |
Duffy states — twice — that CME's capital-efficiency benefit is "over $95 billion" per day, the headline company-wide figure. Later on the identical call, Mike Dennis cites "$27 billion a day" using near-identical all-encompassing wording — roughly a third of Duffy's figure — with neither speaker flagging the other's number or scoping the gap. The identical pattern recurs verbatim one call earlier ($80B vs. $25B). Plausibly the smaller figure is a rates/Treasury-specific subtotal rather than the company-wide number, but that scope distinction is never made explicit, so as reported the two figures are flatly incompatible on their face.
Reviewed and reconciled, not counted as contradictions: (1) ADV superlative framing ("second-highest Q2" vs. "third-highest quarter overall" — a scope difference, not a conflict); (2) dividend yield (2.09% regular-only vs. 4.73% inclusive of the variable dividend — differing bases, not a substantive contradiction). No contradictions found in the quarter-over-quarter narrative on market-data drivers, launch timing, or Compute Futures/Project Vault commentary.
Sources: CME_FY2025Q3.txt, CME_FY2025Q4.txt, CME_FY2026Q1.txt, CME_FY2026Q2.txt (transcripts, this workspace); company_context.md; internal_context/local_facts.md.
Indirect read-throughs
Macro commentary
| Theme | Quote | Read-through |
|---|---|---|
| Rates / Fed leadership | "We have a new Fed chair who is committed to overhauling their communication style." — Mike Dennis | Noisier Fed messaging supports CME's rates-complex hedging/speculation volume near-term. |
| Sovereign debt / Treasury issuance | "We continue to see record debt levels in this country... alongside the $27 billion a day in margin savings." — Mike Dennis | Growing Treasury float structurally supports Treasury futures/BrokerTec volumes over time. |
| Regulatory/clearing mandate | "The Treasury and repo clearing mandate [will be] phased in over the next year." — Mike Dennis | Confirms the UST/repo central-clearing mandate remains on track — relevant to any name exposed to repo/Treasury market structure. |
| Geopolitical / energy volatility | "It's in the headlines today as it relates to the Iranian war" — Terry Duffy | Confirms live geopolitical risk premium in oil; commercial hedgers using CME futures (not perpetuals) to manage exposure. |
| Industrial / supply-chain policy (Project Vault) | "...record amounts of physical copper in COMEX warehouses, just under 700,000 short tons... record open interest in our steel complex." — Derek Sammann | Bullish onshoring/reshoring signal for U.S. industrial materials producers and metals-adjacent logistics. |
| AI / data-center capex as macro driver | "Data centers are front and center of driving economic growth, and AI is in the middle of every conversation right now." — Derek Sammann | A new futures product (Compute Futures) is being built around AI data-center economics — signals durable, volatile capex/hedging demand tied to AI infrastructure. |
| Retail trading engagement | Simulated-trading accounts +56% YoY; 140K+ accounts trading event contracts (+13% QoQ); prediction-market ADV >4M/day (+40% QoQ) | Continued strong retail participation/risk appetite in derivatives-adjacent products — a soft consumer-engagement read. |
Companies mentioned
| Company | Relationship | Read-through |
|---|---|---|
| Kalshi | Competitor (perpetual futures / prediction markets) | CME sizes Kalshi's crypto perp at ~1/20th-1/40th of CME's daily notional and ~1/900th of open interest — worse for Kalshi's stated competitive threat (CME's own framing). |
| ICE | Competitor (energy futures) | Neutral-to-positive — CME cites ICE's energy contracts as a legitimate, complementary hedging venue, implying commercial energy demand supports both venues. |
| S&P Global / Nasdaq / FTSE Russell | Index-licensing partners | Positive — CME's exclusive index-futures licensing rights extend to new product categories (single-stock futures, potential equity perps), implying incremental licensing revenue for the index owners. |
| NVIDIA | Referenced benchmark asset (Compute Futures) | Indirect read only — H100 rental rates as the chosen benchmark signals continued GPU-capacity scarcity/pricing tightness, not a direct comment on NVIDIA's business. |
| Silicon Data | New price-reporting partner (Compute Futures) | Positive — new, likely revenue-generating role as the official price-reporting agency underpinning a CME-listed benchmark. |
| NinjaTrader / Topstep | Retail-distribution/prop-trading partners | Positive — named as committed, growing channels for CME retail volume; prop-trading/funded-trader channel framed as a durable, "educational" on-ramp. |
| CFTC (Chairman Mike Selig) | Regulator | Continued regulatory scrutiny/inconsistency on self-certified 24/7 launches — active litigation overhang on CME's ability to unilaterally launch novel contracts near-term. |
Data sourced from the CME Group FY2026Q2 earnings call transcript (2026-07-22); no Daloopa fundamental IDs applicable to this qualitative task.
Data sourced from Daloopa (company_id 333), CME FY2026Q2 earnings call transcript (2026-07-22), and web-aggregated consensus/press coverage (last resort where Bloomberg/Visible Alpha were offline this run, flagged inline). Prepared July 25, 2026 for the FY2026Q2 print reported July 22, 2026 (BMO).